TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3858912

Group type: EXPERIMENTAL
Intervention: 1 microgram PGE1‐carbinol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 micrograms PGE1‐carbinol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 30 micrograms PGE1‐carbinol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 55 micrograms PGE2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 400 micrograms fenoterol
Number of subjects: 15
Study: 31285094

Group type: EXPERIMENTAL
Intervention: Margin <3 mm (n=47)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Margin ≥3 mm to <8 mm (n=48)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Margin ≥8 mm (n=17)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of margins <8 mm (group 1 and 2)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Overall survival, disease-free and metastasis-free survivals
Number of subjects: 112
Study: 29374526

Group type: EXPERIMENTAL
Intervention: Small monetary incentives ($1/session, maximum of $5/week)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Charitable donations in the same amount ($1/session, maximum of $5/week)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 75
Study: 27724929

Group type: EXPERIMENTAL
Intervention: Hepatic inflow occlusion (Pringle maneuver)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No hepatic inflow occlusion
Number of subjects: 114
Study: 24621953

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) given once a month (IPTm)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) given once a school term (IPTst)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study: 22316868

Group type: EXPERIMENTAL
Intervention: Newly-designed insole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Commercially available insole 1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Commercially available insole 2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Barefoot condition
Number of subjects: 30
Study: 20613689

Group type: EXPERIMENTAL
Intervention: APEC (Anesthesia Preoperative Evaluation Clinic)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Ward assessment
Number of subjects: 207
Study: 17390144

Group type: EXPERIMENTAL
Intervention: Balsalazide 2.25 g daily for 10 days every month plus VSL#3 450 billions/day for 15 days every month
Number of subjects: 30

Group type: COMPARATOR
Intervention: VSL#3 alone 450 billions/day for 15 days every month
Number of subjects: 30
Study: 15668539

Group type: EXPERIMENTAL
Intervention: fosamprenavir/RTV 700/100 mg (arm B)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: LPV/RTV/fosamprenavir 400/100/700 mg (arm C)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: LPV/RTV 400/100 mg (arm A)
Number of subjects: 33
Study: 12014729

Group type: COMPARATOR
Intervention: Interferon alone (6 MU three times a week)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Phlebotomy until iron depletion followed by interferon (6 MU three times a week)
Number of subjects: 114
Study: 9773135

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study: 7636540

Group type: EXPERIMENTAL
Intervention: Dexverapamil (escalated from 240 to 1,200 mg/m2/d) combined with EPOCH chemotherapy
Number of subjects: 154

Group type: COMPARATOR
Intervention: EPOCH chemotherapy alone
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Dexverapamil
Number of subjects: 154
Study: 2247813

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy for gallbladder stones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy for bile duct stones
Number of subjects: 0
Study: 345414

Group type: EXPERIMENTAL
Intervention: Methylated analogues of prostaglandin E2 administered orally
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 30449531

Group type: EXPERIMENTAL
Intervention: Drift-diffusion model-derived attention bias indices
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Automated attention retraining procedure
Number of subjects: 70
Study: 28663304

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mixed-meal tolerance test
Number of subjects: 72
Study: 26429629

Group type: EXPERIMENTAL
Intervention: ORALMENT (L-menthol oral administration)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SKINMENT (L-menthol skin administration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: ORALCON (control for oral administration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SKINCON (control for skin administration)
Number of subjects: 20
Study: 23883424

Group type: EXPERIMENTAL
Intervention: 10 mL syringe
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 20 mL syringe
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 30 mL syringe
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 60 mL syringe
Number of subjects: 48
Study: 21834476

Group type: EXPERIMENTAL
Intervention: Oversewing the staple line with a polypropylene 3‐0 running suture (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No oversewing of the staple line (Group B)
Number of subjects: 100
Study: 19523617

Group type: EXPERIMENTAL
Intervention: Single medium continuously, without medium renewal on day 3
Number of subjects: 893

Group type: COMPARATOR
Intervention: Sequential media
Number of subjects: 893
Study: 16643233

Group type: EXPERIMENTAL
Intervention: 1.5 mg/ml levobupivacaine via CEI (15 mg/h)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 5 mg/ml levobupivacaine via CEI (15 mg/h)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 1.5 mg/ml levobupivacaine via PCEA (5 mg bolus, 20 min lockout)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 5 mg/ml levobupivacaine via PCEA (5 mg bolus, 20 min lockout)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 82
Study: 15292626

Group type: EXPERIMENTAL
Intervention: Combined treatment of cognitive-behavioral therapy and ethyl loflazepate (2 mg daily) for 6 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Antianxiety agent only (ethyl loflazepate) for 6 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combined treatment group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Medication only group
Number of subjects: 42
Study: 11321637

Group type: EXPERIMENTAL
Intervention: Self-study of chess positions (500 positions over several months, 15-30 minutes daily)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Chunk construction based on the neighbourhood of associated pieces
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Frequency-based correlative association process
Number of subjects: 2
Study: 9008371

Group type: EXPERIMENTAL
Intervention: Expectancy-congruent distortion of midterm grades when expectancy and liking matched.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expectancy-discontinued condition when expectancy and liking mismatched.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Order of expectancy and liking information.
Number of subjects: 0
Study: 8509240

Group type: EXPERIMENTAL
Intervention: Bench Stepping (BS) at 30 and 32 step cycles.min‐1 with bench heights (BH) of 15.2, 30.4, 25.4, and 30.5 cm.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Treadmill walking/running (TM)
Number of subjects: 28
Study: 3323852

Group type: EXPERIMENTAL
Intervention: Sequential oestrogen/progestogen therapy (4 mg, 2 mg, and 1 mg 17 beta‐oestradiol combined with 1 mg norethisterone acetate)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 30992026

Group type: EXPERIMENTAL
Intervention: Theoretical geometric model developed based on specific morphometrics from C-T sections.
Number of subjects: 9
Study: 28060713

Group type: EXPERIMENTAL
Intervention: Boost.SH
Number of subjects: 0

Group type: COMPARATOR
Intervention: AdaBoost
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiview kernel learning algorithm
Number of subjects: 0
Study: 26777721

Group type: EXPERIMENTAL
Intervention: Real-time daily patient feedback to providers along with provider coaching and revisits of patients not reporting optimal satisfaction with their care.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not receiving real-time feedback).
Number of subjects: 0
Study: 25178594

Group type: EXPERIMENTAL
Intervention: Azithromycin at a dose of 10mg/kg/day for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cefixime at a dose of 20mg/kg/day in two divided doses for 14 days
Number of subjects: 60
Study: 21819813

Group type: EXPERIMENTAL
Intervention: Thought Records (TRs)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Behavioral Experiments (BEs)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 91
Study: 20463186

Group type: EXPERIMENTAL
Intervention: RTX 2 x 500 mg
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Dose escalation (2 x 500 mg to 2 x 1000 mg)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: RTX 2 x 1000 mg
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: All RTX regimens
Number of subjects: 346
Study: 16855773

Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG) 1,000 mg (3 times daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16163531

Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg SR)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Methamphetamine (0, 15, and 30 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11921421

Group type: EXPERIMENTAL
Intervention: losartan 50 mg daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 10091831

Group type: EXPERIMENTAL
Intervention: i.c. adenosine (2.4 mg/min for 10 min starting 20 min before the first occlusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 30
Study: 7594412

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics or beta-blockers (first- or second-line drugs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretic treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of diastolic hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of isolated systolic hypertension
Number of subjects: 0
Study: 2221964

Group type: EXPERIMENTAL
Intervention: Gradual refeeding after rehydration
Number of subjects: 62

Group type: COMPARATOR
Intervention: Abrupt refeeding after rehydration
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Lactose free soya based formula
Number of subjects: 62
Study: 392739

Group type: EXPERIMENTAL
Intervention: Sulfamethizole
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sulfamethoxazole
Number of subjects: 112
Study: 31654643

Group type: EXPERIMENTAL
Intervention: Lidocaine‐epinephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prilocaine‐felypressin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study: 31238886

Group type: EXPERIMENTAL
Intervention: Partnership intervention (video consultations between cancer patient, general practitioner, and oncologist)
Number of subjects: 278
Study: 28577292

Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg/day for 12 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 26446779

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored interventions
Number of subjects: 7
Study: 23356388

Group type: EXPERIMENTAL
Intervention: Conversations regarding dietary habits
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Conversations regarding physical activity
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Conversations regarding physical examinations
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Conversations regarding child engagement
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Conversations regarding language skills
Number of subjects: 23
Study: 20204975

Group type: EXPERIMENTAL
Intervention: Full intervention (peer-modelling materials, daily pedometer goals, rewards)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: No-rewards intervention (peer-modelling materials, daily pedometer goals, no rewards)
Number of subjects: 386

Group type: COMPARATOR
Intervention: No intervention (control group, wore pedometers only)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: No-rewards intervention (after taper phase)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Full intervention (after taper phase)
Number of subjects: 386
Study: 19751560

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (standard treatment without low-dose hydrocortisone)
Number of subjects: 77
Study: 17299470

Group type: EXPERIMENTAL
Intervention: 5 mg of oral riboflavin and other B-group vitamins daily for 14 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: No B-vitamins for 14 days (Control group)
Number of subjects: 96
Study: 15496622

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 421

Group type: COMPARATOR
Intervention: Postoperative chemoradiotherapy
Number of subjects: 421
Study: 11486924

Group type: EXPERIMENTAL
Intervention: Visual presentation of words
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aural presentation of words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spoken recall mode
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orienting task with aural presentation
Number of subjects: 0
Study: 9934234

Group type: EXPERIMENTAL
Intervention: Computerized simulations
Number of subjects: 38

Group type: COMPARATOR
Intervention: Traditional seminars
Number of subjects: 38
Study: 7923916

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (age-matched controls)
Number of subjects: 0
Study: 2839538

Group type: EXPERIMENTAL
Intervention: 5 mg iv bolus dose of methoxamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30457655

Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab dosing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treat-and-extend (T&E) ranibizumab dosing
Number of subjects: 20
Study: 28657367

Group type: COMPARATOR
Intervention: 0.25 mm nanotips
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.5 mm nanotips
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.5 mm traditional micro-needles
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.25 mm traditional micro-needles
Number of subjects: 16
Study: 25764996

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 1 year in infants (m/f: 11/8)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 2 years in prepubertal children (m/f: 14/14)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 47
Study: 24092509

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil intravenous anaesthesia
Number of subjects: 83

Group type: COMPARATOR
Intervention: Desflurane/fentanyl general anaesthesia
Number of subjects: 83

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil
Number of subjects: 83
Study: 21045734

Group type: EXPERIMENTAL
Intervention: Intensive treatment with amlodipine/valsartan 10/320 mg (after dose increase at week 2) and hydrochlorothiazide 12.5 mg (added at week 4)
Number of subjects: 728

Group type: COMPARATOR
Intervention: Moderate treatment with amlodipine/valsartan 5/160 mg and hydrochlorothiazide 12.5 mg (added at week 4)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Intensive treatment with amlodipine/valsartan 10/320 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 728

Group type: COMPARATOR
Intervention: Moderate treatment with amlodipine/valsartan 5/160 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 728
Study: 18565008

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention based on the chronic care model, including patient and provider activation and education, patient assessment, outcomes monitoring, and feedback to providers over 12 months.
Number of subjects: 401
Study: 16873425

Group type: EXPERIMENTAL
Intervention: First-line capecitabine, second-line irinotecan, third-line capecitabine + oxaliplatin (arm A)
Number of subjects: 820

Group type: COMPARATOR
Intervention: First-line capecitabine + irinotecan, second-line capecitabine + oxaliplatin (arm B)
Number of subjects: 820
Study: 12973957

Group type: EXPERIMENTAL
Intervention: Cryoprecipitate (5 units)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Fresh Frozen Plasma (FFP, 4 units)
Number of subjects: 17
Study: 10900813

Group type: EXPERIMENTAL
Intervention: Experimental leaders led to believe their trainees had higher than usual potential
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 8695601

Group type: EXPERIMENTAL
Intervention: Polysaccharide-free diet with breakfast supplement (biscuits made from wheat, potato, or banana flours; moist-heat-processed wheat or maize flours)
Number of subjects: 9
Study: 1290920

Group type: EXPERIMENTAL
Intervention: terazosin
Number of subjects: 17

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 17
Study: 6386028

Group type: EXPERIMENTAL
Intervention: SHRZ6 regimen (6 months of isoniazid and rifampicin supplemented for the first 2 months by streptomycin and pyrazinamide)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: EHRZ6 regimen (6 months of isoniazid and rifampicin supplemented for the first 2 months by ethambutol and pyrazinamide)
Number of subjects: 444

Group type: COMPARATOR
Intervention: EHR9 regimen (9 months of isoniazid and rifampicin supplemented for the first 2 months by ethambutol)
Number of subjects: 444
Study: 30144084

Group type: EXPERIMENTAL
Intervention: Atopic sensitization at the time of the first wheezing episode
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Bronchial reactivity after exercise challenge or bronchodilation
Number of subjects: 76
Study: 28481823

Group type: EXPERIMENTAL
Intervention: DASH online education modules
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity (PA)
Number of subjects: 26
Study: 26825826

Group type: EXPERIMENTAL
Intervention: Robotic radical hysterectomy (RRH) plus pelvic lymphadenectomy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Laparoscopic radical hysterectomy plus pelvic lymphadenectomy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy plus pelvic lymphadenectomy
Number of subjects: 41
Study: 23128847

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) 3x a week at individual anaerobic threshold
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) 10 Hz, 20s 'on'/20s 'off', applied to leg extensors for 2 h/day
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combination of AT and EMS (AT+EMS)
Number of subjects: 71
Study: 22320418

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%/timolol maleate 0.5% fixed combination (LTFC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Dorzolamide hydrochloride 2%/timolol maleate 0.5% fixed combination (DTFC)
Number of subjects: 33
Study: 21145518

Group type: EXPERIMENTAL
Intervention: Stretching treatment performed by physical therapists
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stretching treatment performed by parents
Number of subjects: 20
Study: 17420419

Group type: COMPARATOR
Intervention: Cocoa products (median duration 2 weeks)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Black and green tea (median duration 4 weeks)
Number of subjects: 516
Study: 15640320

Group type: EXPERIMENTAL
Intervention: CRQ-Self-Administered (CRQ-SA)
Number of subjects: 177

Group type: COMPARATOR
Intervention: CRQ-Interviewer Administered (CRQ-IA)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Standardised dyspnoea domain
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Individualised dyspnoea domain
Number of subjects: 177
Study: 17823666

Group type: EXPERIMENTAL
Intervention: Alcohol-based mouthrinse
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonalcohol-based mouthrinse
Number of subjects: 20
Study: 10867767

Group type: EXPERIMENTAL
Intervention: Percutaneous transmyocardial laser revascularization (PTMR)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 550
Study: 8792352

Group type: EXPERIMENTAL
Intervention: Opsite 3000TM (transparent moisture vapor permeable dressings, MVPD) changed weekly
Number of subjects: 101

Group type: COMPARATOR
Intervention: Dry, sterile gauze dressing (DSGD) changed every 24 hours
Number of subjects: 101
Study: 1480726

Group type: EXPERIMENTAL
Intervention: structured and modularized skills training
Number of subjects: 41

Group type: COMPARATOR
Intervention: supportive group psychotherapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: skills training
Number of subjects: 41
Study: 6734061

Group type: EXPERIMENTAL
Intervention: Ambulant group (allowed to be fully ambulant)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bed rest group (confined to bed for 24 h)
Number of subjects: 200
Study: 31586879

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination with controlled ovarian hyperstimulation (IUI‐COH)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Modified natural cycle in vitro fertilization (IVF‐MNC)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Single embryo transfer IVF (IVF‐SET)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Naturally conceived group
Number of subjects: 333
Study: 30282056

Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAU plus the Youth Outcomes Questionnaire (YOQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 27402969

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 2060